PurposeTo assess the effect of an intravitreal ocriplasmin injection on visual function, measured using visual acuity (VA) and vision‐related quality of life.Methods
Post hoc analysis of prespecified secondary end‐points in two multicentre, randomized, double‐masked, phase 3 clinical trials. A total of 652 participants with symptomatic vitreomacular adhesion were enrolled, of whom 464 received a single intravitreal injection of 125 μg ocriplasmin and 188 received a single intravitreal placebo injection. Based on principal components analysis results, visual function response (VFR) was defined as either a VA improvement of ≥2 lines; or an improvement in the composite score of the National Eye Institute Visual Function Questionnaire (VFQ‐25) exceeding the minimal clinically important difference (MCID), estimated using the standard error of measurement approach; or an improvement in the VFQ‐25 driving subscale score exceeding the MCID. The main outcome measure was VFR at 6 months.ResultsA VFR occurred in 55.1% of the ocriplasmin group versus 34.2% of the placebo injection group (p < 0.0001). This comprised 23.7% versus 11.2% (p = 0.0003) with a ≥ 2‐line VA improvement, 35.9% versus 22.7% (p = 0.0016) for the VFQ‐25 composite score, and 10.2% versus 6.2% (p = 0.1697) for the driving subscale.ConclusionOcriplasmin produces a clinically meaningful visual function benefit.